Who owns C4 Therapeutics, Inc.?
Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Institutional ownership of CCCC from SEC Form 13F filings across 151 reporting managers. All positions are from one synchronized reporting period — 2026-09-30 books, filed up to 45 days after quarter end — so every row is comparable.
As of the 2026-09-30 reporting period, 151 institutions disclosed 137.6M shares of C4 Therapeutics, Inc. worth $457.3M — about 101.1% of shares outstanding; the largest disclosed holder is Squadron Capital Management LLC. Source: SEC Form 13F filings, parsed by EvidInvest.
151
13F holders
$457.3M
value, 2026 filers
101.1%
of shares outstanding (137.6M sh)
28
new positions (2026 filers)
Top institutional holders
ordered by shares owned · positions as of 2026-09-30 · % of fund = share of the manager's own book · % of co. = share of CCCC's shares outstanding
| # | Manager | Shares | Value | % of fund | % of co. | Δ shares QoQ |
|---|---|---|---|---|---|---|
| 1 | Squadron Capital Management LLC | 9.3M | $31.0M | 7.8% | 6.8% | +29.4% |
| 2 | MORGAN STANLEY | 8.9M | $29.5M | 0.0% | 6.5% | +0.1% |
| 3 | RA CAPITAL MANAGEMENT, L.P. | 8.2M | $27.3M | 0.3% | 6% | +2.4% |
| 4 | BlackRock, Inc. | 8.2M | $27.2M | 0.0% | 6% | +3.6% |
| 5 | Lynx1 Capital Management LP | 7.5M | $25.1M | 3.9% | 5.5% | +2.8% |
| 6 | Bain Capital Life Sciences Investors, LLC | 7.2M | $23.9M | 1.6% | 5.3% | 0.0% |
| 7 | CITADEL ADVISORS LLC | 5.0M | $16.7M | 0.0% | 3.7% | +19.6% |
| 8 | JPMORGAN CHASE & CO | 4.7M | $14.7M | 0.0% | 3.5% | -1.1% |
| 9 | GOLDMAN SACHS GROUP INC | 4.7M | $15.6M | 0.0% | 3.4% | +32.6% |
| 10 | VANGUARD CAPITAL MANAGEMENT LLC | 4.6M | $15.3M | 0.0% | 3.4% | +3.7% |
| 11 | WASATCH ADVISORS LP | 4.2M | $13.9M | 0.1% | 3.1% | +18.1% |
| 12 | Boxer Capital Management, LLCNEW | 4.2M | $13.8M | 1.2% | 3% | new |
| 13 | TWO SIGMA INVESTMENTS, LP | 3.7M | $12.5M | 0.0% | 2.8% | +8.0% |
| 14 | SILVERARC CAPITAL MANAGEMENT, LLC | 3.5M | $11.5M | 1.3% | 2.5% | +13.9% |
| 15 | Soleus Capital Management, L.P. | 3.4M | $11.2M | 0.4% | 2.5% | -0.6% |
| 16 | STEMPOINT CAPITAL LP | 3.3M | $11.0M | 2.0% | 2.4% | +528.9% |
| 17 | BANK OF AMERICA CORP /DE/ | 2.9M | $9.6M | 0.0% | 2.1% | +8.8% |
| 18 | Candriam S.C.A. | 2.8M | $9.2M | 0.0% | 2% | +53.6% |
| 19 | GEODE CAPITAL MANAGEMENT, LLC | 2.7M | $9.0M | 0.0% | 2% | +7.0% |
| 20 | Qube Research & Technologies Ltd | 2.4M | $8.0M | 0.0% | 1.8% | +546.9% |
| 21 | ADAR1 Capital Management, LLC | 2.2M | $7.4M | 0.3% | 1.6% | +664.8% |
| 22 | STATE STREET CORP | 2.2M | $7.4M | 0.0% | 1.6% | +4.9% |
| 23 | D. E. Shaw & Co., Inc. | 2.2M | $7.2M | 0.0% | 1.6% | +24.2% |
| 24 | Ikarian Capital, LLC | 1.9M | $6.4M | 0.6% | 1.4% | -20.6% |
| 25 | ACADIAN ASSET MANAGEMENT LLC | 1.8M | $6.0M | 0.0% | 1.3% | -1.0% |
Source: SEC Form 13F-HR filings (institutional managers over $100M in US-listed positions). 13Fs disclose long positions only, up to 45 days after quarter end; each manager's latest filed quarter is shown per row and dollar values are the manager's filed marks. Aggregates labeled "2026 filers" count only managers whose latest book is a 2026 quarter. Related: valuation · options positioning · supply chain. Research, not investment advice.